Genentech appears poised to announce 70 percent revenue growth for 2006, a monumental increase for a company that started out 30 years ago as a small biotech operation. The huge growth is due to new sales of Lucentis [1] with expanding markets for Avastin [2], Rituxan [3] and Herceptin [4]. But with its pipeline of new drug prospects growing thin, the focus at Genentech now is beefing up its R&D efforts. Execs say they're hiring new researchers as fast as they can to go to work on a new generation of biologics. Analysts worry that the spectacular growth will have to soon flag as revenue growth begins to settle in at a more measured pace.

- read the article [5] on Genentech's strategy from The Wall Street Journal (sub. req.)

Related Articles:
Genentech strikes $919M deal to buy Tanox. Report [6]
Genentech inks $300M pact with Swiss biotech. Report [7]